SG11201401992YA - Heteroaryl pyridone and aza-pyridone compounds as inhibitors of btk activity - Google Patents

Heteroaryl pyridone and aza-pyridone compounds as inhibitors of btk activity

Info

Publication number: SG11201401992YA
Authority: SG; Singapore
Prior art keywords: pyridone; aza; inhibitors; heteroaryl; btk activity
Prior art date: 2011-11-03

Application number

SG11201401992YA

Other languages

English (en)

Inventor

James John Crawford

Daniel Fred Ortwine

Binqing Wei

Wendy B Young

Original Assignee

Hoffmann La Roche

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2011-11-03

Filing date

2012-11-02

Publication date

2014-05-29

2012-11-02 Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche

2014-05-29 Publication of SG11201401992YA publication Critical patent/SG11201401992YA/en

Links

-1 Heteroaryl pyridone Chemical compound 0.000 title 1
239000003112 inhibitor Substances 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/14—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D495/14—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
- C07F7/1804—Compounds having Si-O-C linkages

Landscapes

Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Epidemiology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Plural Heterocyclic Compounds (AREA)

SG11201401992YA 2011-11-03 2012-11-02 Heteroaryl pyridone and aza-pyridone compounds as inhibitors of btk activity SG11201401992YA (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201161555393P	2011-11-03	2011-11-03
PCT/US2012/063194 WO2013067274A1 (en)	2011-11-03	2012-11-02	Heteroaryl pyridone and aza-pyridone compounds as inhibitors of btk activity

Publications (1)

Publication Number	Publication Date
SG11201401992YA true SG11201401992YA (en)	2014-05-29

Family

ID=47146779

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SG11201401992YA SG11201401992YA (en)	2011-11-03	2012-11-02	Heteroaryl pyridone and aza-pyridone compounds as inhibitors of btk activity

Country Status (34)

Country	Link
US (11)	US8716274B2 (2)
EP (5)	EP4019508A1 (2)
JP (5)	JP5976827B2 (2)
KR (2)	KR101659193B1 (2)
CN (2)	CN104125959B (2)
AR (2)	AR088641A1 (2)
AU (5)	AU2012332365B2 (2)
CA (1)	CA2853975C (2)
CL (1)	CL2014001103A1 (2)
CO (1)	CO6950472A2 (2)
CR (1)	CR20140194A (2)
CY (1)	CY1117097T1 (2)
DK (2)	DK3002284T3 (2)
EA (1)	EA023263B1 (2)
ES (3)	ES2738329T3 (2)
HR (2)	HRP20151442T1 (2)
HU (2)	HUE044959T2 (2)
IL (1)	IL232060A (2)
IN (1)	IN2014CN03250A (2)
LT (1)	LT3002284T (2)
MA (1)	MA35819B1 (2)
MX (2)	MX2014005331A (2)
PE (1)	PE20141586A1 (2)
PH (1)	PH12014500936A1 (2)
PL (3)	PL3521288T3 (2)
PT (2)	PT2773638E (2)
RS (2)	RS59016B1 (2)
SG (1)	SG11201401992YA (2)
SI (2)	SI3002284T1 (2)
TR (1)	TR201909849T4 (2)
TW (4)	TWI609868B (2)
UA (1)	UA111756C2 (2)
WO (1)	WO2013067274A1 (2)
ZA (1)	ZA201804727B (2)

Families Citing this family (77)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
UA111756C2 (uk) *	2011-11-03	2016-06-10	Ф. Хоффманн-Ля Рош Аг	Сполуки гетероарилпіридону та азапіридону як інгібітори тирозинкінази брутона
EP2773639B1 (en) *	2011-11-03	2017-04-26	F. Hoffmann-La Roche AG	Alkylated piperazine compounds as inhibitors of btk activity
WO2015000949A1 (en)	2013-07-03	2015-01-08	F. Hoffmann-La Roche Ag	Heteroaryl pyridone and aza-pyridone amide compounds
WO2015050703A1 (en) *	2013-10-04	2015-04-09	Yi Chen	Inhibitors of bruton's tyrosine kinase
WO2015082583A1 (en)	2013-12-05	2015-06-11	F. Hoffmann-La Roche Ag	Heteroaryl pyridone and aza-pyridone compounds with electrophilic functionality
CN106922146B (zh)	2014-10-02	2020-05-26	豪夫迈·罗氏有限公司	用于治疗由布鲁顿酪氨酸激酶(btk)介导的疾病的吡唑甲酰胺化合物
JP6368043B2 (ja)	2014-10-27	2018-08-01	エフ．ホフマン−ラロシュアーゲーＦ．Ｈｏｆｆｍａｎｎ−ＬａＲｏｃｈｅＡｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ	三環式ラクタム化合物の製造法
CN106188063A (zh) *	2015-05-08	2016-12-07	中国科学院上海药物研究所	用作Lp-PLA2抑制剂的双环类化合物、其制备方法及医药用途
JP6532599B2 (ja)	2015-09-02	2019-06-19	グラクソスミスクライン、インテレクチュアル、プロパティー、（ナンバー２）、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅＩｎｔｅｌｌｅｃｔｕａｌＰｒｏｐｅｒｔｙ（Ｎｏ．２）Ｌｉｍｉｔｅｄ	ブロモドメイン阻害薬としての使用のためのピリジノンジカルボキサミド
US10208024B2 (en)	2015-10-23	2019-02-19	Array Biopharma Inc.	2-aryl- and 2-heteroaryl-substituted 2-pyridazin-3(2H)-one compounds as inhibitors of FGFR tyrosine kinases
US20200270265A1 (en) *	2016-02-19	2020-08-27	Novartis Ag	Tetracyclic pyridone compounds as antivirals
WO2017148837A1 (en) *	2016-02-29	2017-09-08	F. Hoffmann-La Roche Ag	Dosage form compositions comprising an inhibitor of bruton's tyrosine kinase
JP6983813B2 (ja) *	2016-04-28	2021-12-17	エフ.ホフマン−ラロシュアーゲーF. Hoffmann−La Roche Aktiengesellschaft	２−ピラゾロ［１，５−ａ］ピラジン−２−イルピリド［１，２−ａ］ピリミジン−４−オンの調製のためのプロセス
CN108101905A (zh) *	2016-11-24	2018-06-01	中国科学院上海药物研究所	嘧啶并[5,4-b]吲嗪或嘧啶并[5,4-b]吡呤化合物、其制备方法及用途
CA3045339A1 (en)	2016-12-03	2018-06-07	Juno Therapeutics, Inc.	Methods and compositions for use of therapeutic t cells in combination with kinase inhibitors
KR20190112263A (ko)	2016-12-12	2019-10-04	멀티비르 인코포레이티드	암 및 감염성 질환의 치료 및 예방을 위한 바이러스 유전자 치료요법 및 면역 체크포인트 억제제를 포함하는 방법 및 조성물
WO2018109050A1 (en) *	2016-12-15	2018-06-21	F. Hoffmann-La Roche Ag	Process for preparing btk inhibitors
WO2018113771A1 (en)	2016-12-22	2018-06-28	Betta Pharmaceuticals Co., Ltd	Benzimidazole derivatives, preparation methods and uses theirof
CN110709702A (zh) *	2017-03-24	2020-01-17	豪夫迈·罗氏有限公司	治疗自身免疫性疾病和炎性疾病的方法
CN107445981B (zh) *	2017-08-25	2018-06-22	牡丹江医学院	一种用于防治宫颈炎的活性化合物
KR102613433B1 (ko)	2017-10-11	2023-12-13	주식회사 대웅제약	신규한 페닐피리딘 유도체 및 이를 포함하는 약학 조성물
CN111386272B (zh)	2017-10-27	2023-01-06	费森尤斯卡比肿瘤学有限公司	一种改进的瑞博西尼及其盐的制备方法
KR102861971B1 (ko)	2018-02-19	2025-09-19	광조우 루펭 파마슈티칼 컴퍼니 엘티디.	Btk 및 그의 돌연변이체의 억제제
TWI801517B (zh)	2018-03-12	2023-05-11	加拿大商愛彼特生物製藥公司	經取代的2-吡啶酮三環化合物、其類似物及其使用方法
WO2019208805A1 (ja)	2018-04-27	2019-10-31	小野薬品工業株式会社	Ｂｔｋ阻害活性を有する化合物を有効成分として含む自己免疫疾患の予防および／または治療剤
CN112839648B (zh)	2018-06-07	2025-04-04	达萨玛治疗公司	Sarm1抑制剂
KR20210038877A (ko)	2018-07-25	2021-04-08	노파르티스 아게	Nlrp3 인플라마좀 억제제
KR102328682B1 (ko) *	2018-08-27	2021-11-18	주식회사 대웅제약	신규한 헤테로사이클릭아민 유도체 및 이를 포함하는 약학 조성물
CA3111126A1 (en)	2018-08-31	2020-03-05	Stichting Katholieke Universiteit	Synergistic combinations of amino acid depletion agent sensitizers (aadas) and amino acid depletion agents (aada), and therapeutic methods of use thereof
MX2021004191A (es)	2018-10-15	2021-05-27	Nurix Therapeutics Inc	Compuestos bifuncionales para degradar la tirosina cinasa de bruton (btk) mediante la trayectoria de ubiquitina proteosoma.
EP3898626A1 (en)	2018-12-19	2021-10-27	Array Biopharma, Inc.	Substituted pyrazolo[1,5-a]pyridine compounds as inhibitors of fgfr tyrosine kinases
EP3897670A4 (en)	2018-12-19	2022-09-07	Disarm Therapeutics, Inc.	MRSA1 INHIBITORS IN COMBINATION WITH NEUROPROTECTIVE AGENTS
US12351571B2 (en)	2018-12-19	2025-07-08	Array Biopharma Inc.	Substituted quinoxaline compounds as inhibitors of FGFR tyrosine kinases
TW202033523A (zh) *	2019-01-17	2020-09-16	美商愛彼特生物製藥股份有限公司	經取代的多環羧酸、其類似物及使用其之方法
TW202042815A (zh)	2019-01-22	2020-12-01	美商建南德克公司	使用布魯頓（bruton）酪胺酸激酶抑制劑治療類風性關節炎、慢性自發性蕁麻疹及全身性紅斑性狼瘡的方法
US12582722B2 (en)	2019-02-13	2026-03-24	Nurix Therapeutics, Inc.	Bifunctional compounds for degrading BTK via ubiquitin proteosome pathway
WO2020176403A1 (en)	2019-02-25	2020-09-03	Newave Pharmaceutical Inc.	Inhibitor of btk and mutants thereof
EA202192575A1 (ru)	2019-03-21	2022-01-14	Онксео	Соединения dbait в сочетании с ингибиторами киназ для лечения рака
CA3136348A1 (en)	2019-04-09	2020-10-15	Nurix Therapeutics, Inc.	3-substituted piperidine compounds for cbl-b inhibition, and use of a cbl-b inhibitor in combination with a cancer vaccine and/or oncolytic virus
AR119731A1 (es)	2019-05-17	2022-01-05	Novartis Ag	Inhibidores del inflamasoma nlrp3
AU2020278592B2 (en)	2019-05-17	2024-10-10	Nurix Therapeutics, Inc.	Cyano cyclobutyl compounds for Cbl-b inhibition and uses thereof
MX2021015675A (es)	2019-06-26	2022-02-03	Nurix Therapeutics Inc	Compuestos de bencil-triazol sustituidos para la inhibicion de cbl-b y otros usos de los mismos.
EP4034140A1 (en)	2019-09-24	2022-08-03	Nurix Therapeutics, Inc.	Cbl inhibitors and compositions for use in adoptive cell therapy
US20220363689A1 (en)	2019-10-05	2022-11-17	Newave Pharmaceutical Inc.	Inhibitor of btk and mutants thereof
US20230024442A1 (en) *	2019-11-08	2023-01-26	Nurix Therapeutics, Inc.	Bifunctional compounds for grading btk via ubiquitin proteosome pathway
CN114761006A (zh)	2019-11-08	2022-07-15	Inserm(法国国家健康医学研究院)	对激酶抑制剂产生耐药性的癌症的治疗方法
WO2021113557A1 (en)	2019-12-04	2021-06-10	Nurix Therapeutics, Inc.	Bifunctional compounds for degrading btk via ubiquitin proteosome pathway
WO2021148581A1 (en)	2020-01-22	2021-07-29	Onxeo	Novel dbait molecule and its use
IL295589A (en)	2020-02-20	2022-10-01	Hutchison Medipharma Ltd	The heterocyclic heteroaryl compounds and their uses
WO2021173740A1 (en)	2020-02-28	2021-09-02	Genentech, Inc.	Methods of treating primary progressive multiple sclerosis using an inhibitor of bruton's tyrosine kinase
BR112022019846A2 (pt)	2020-04-03	2022-11-22	Genentech Inc	Método de tratamento de esclerose múltipla recorrente (rms), métodos para reduzir a taxa de recorrência anualizada (arr), reduzir o risco de experimentar ccdp12 e aumentar o tempo até o início de ccdp12 e compostos
CN115715291B (zh) *	2020-06-18	2025-04-29	上海华汇拓医药科技有限公司	布鲁顿酪氨酸激酶抑制剂及其制备方法
US20230295109A1 (en) *	2020-08-04	2023-09-21	Hoffmann-La Roche Inc.	Pyridinone compounds for the treatment of autoimmune disease
AU2021326530A1 (en) *	2020-08-14	2023-04-20	Guangzhou Lupeng Pharmaceutical Company Ltd.	Dosage form compositions comprising an inhibitor of btk and mutants thereof
JP7545570B2 (ja)	2020-08-14	2024-09-04	ノバルティスアーゲー	ヘテロアリール置換スピロピペリジニル誘導体及びその薬学的使用
CN121226379A (zh)	2020-09-21	2025-12-30	和记黄埔医药（上海）有限公司	杂芳基杂环化合物及其用途
WO2022094172A2 (en)	2020-10-30	2022-05-05	Newave Pharmaceutical Inc.	Inhibitors of btk
US20240058457A1 (en)	2020-12-20	2024-02-22	Newave Pharmaceutical Inc.	Btk degrader
EP4313023A1 (en)	2021-04-02	2024-02-07	Biogen MA Inc.	Combination treatment methods of multiple sclerosis
WO2022217123A2 (en)	2021-04-08	2022-10-13	Nurix Therapeutics, Inc.	Combination therapies with cbl-b inhibitor compounds
EP4545537A3 (en)	2021-05-05	2025-07-16	F. Hoffmann-La Roche AG	Process for preparing btk inhibitors
CN113603685A (zh) *	2021-07-23	2021-11-05	都创(上海)医药开发有限公司	Fenebrutinib化合物的晶型及其制备方法和用途
CA3236073A1 (en)	2021-10-26	2023-05-04	Robert J. Brown	Piperidinylpyrazine-carboxamide compounds for treating and preventing cancer and for degrading btk
KR20240157639A (ko)	2021-12-14	2024-11-01	크로스파이어 온콜로지 홀딩 비.브이.	거대고리 btk 억제제
US20250136620A1 (en) *	2022-01-17	2025-05-01	Newave Pharmaceutical Inc.	Btk degrader
TW202346276A (zh)	2022-01-27	2023-12-01	日商田邊三菱製藥股份有限公司	新穎之ｂ０ａｔ１抑制劑
WO2023143491A1 (zh)	2022-01-28	2023-08-03	和记黄埔医药（上海）有限公司	7,8-二氢-2h-环戊二烯并吡咯并吡嗪酮化合物的合成方法
UY40374A (es)	2022-08-03	2024-02-15	Novartis Ag	Inhibidores de inflamasoma nlrp3
JPWO2024210198A1 (2)	2023-04-06	2024-10-10
TW202508592A (zh)	2023-05-16	2025-03-01	美商建南德克公司	使用布魯頓酪胺酸激酶之抑制劑來治療復發型多發性硬化症之方法
WO2024246287A1 (en)	2023-06-02	2024-12-05	Crossfire Oncology Holding B.V.	Medical use of a macrocyclic reversible btk inhibitor
WO2024245578A1 (en)	2023-06-02	2024-12-05	Netherlands Translational Research Center Holding B.V.	Therapeutic combinations of an irreversible btk inhibitor and a macrocyclic reversible btk inhibitor
WO2024245577A1 (en)	2023-06-02	2024-12-05	Netherlands Translational Research Center Holding B.V.	Therapeutic combinations of an irreversible btk inhibitor and a reversible btk inhibitor
WO2024256568A1 (en)	2023-06-13	2024-12-19	Crossfire Oncology Holding B.V.	Salt and crystal forms of a macrocyclic btk inhibitor
WO2024256574A1 (en)	2023-06-13	2024-12-19	Crossfire Oncology Holding B.V.	Process for preparing macrocyclic btk inhibitors
WO2025031344A1 (zh) *	2023-08-07	2025-02-13	广州麓鹏制药有限公司	一种丙烯酰胺类化合物的晶型vi及其制备方法和用途
WO2026017823A1 (en)	2024-07-18	2026-01-22	F. Hoffmann-La Roche Ag	Process for preparing btk inhibitor intermediates

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3773919A (en)	1969-10-23	1973-11-20	Du Pont	Polylactide-drug mixtures
US5583024A (en)	1985-12-02	1996-12-10	The Regents Of The University Of California	Recombinant expression of Coleoptera luciferase
US5543523A (en)	1994-11-15	1996-08-06	Regents Of The University Of Minnesota	Method and intermediates for the synthesis of korupensamines
JPH08336393A (ja)	1995-04-13	1996-12-24	Mitsubishi Chem Corp	光学活性なγ−置換−β−ヒドロキシ酪酸エステルの製造法
US6602677B1 (en)	1997-09-19	2003-08-05	Promega Corporation	Thermostable luciferases and methods of production
KR20040024564A (ko)	2001-07-12	2004-03-20	아베시아 리미티드	마이크로캡슐화된 촉매, 이의 제조 방법 및 이의 사용 방법
US7405295B2 (en)	2003-06-04	2008-07-29	Cgi Pharmaceuticals, Inc.	Certain imidazo[1,2-a]pyrazin-8-ylamines and method of inhibition of Bruton's tyrosine kinase by such compounds
WO2005005429A1 (en)	2003-06-30	2005-01-20	Cellular Genomics, Inc.	Certain heterocyclic substituted imidazo[1,2-a]pyrazin-8-ylamines and methods of inhibition of bruton’s tyrosine kinase by such compounds
CA2573644A1 (en)	2004-07-12	2006-02-16	Idun Pharmaceuticals, Inc.	Tetrapeptide analogs
AU2005304473A1 (en)	2004-11-10	2006-05-18	Cgi Pharmaceuticals, Inc.	Imidazo[1 , 2-a] pyrazin-8-ylamines useful as modulators of kinase activity
MX2007011041A (es)	2005-03-10	2008-02-22	Cgi Pharmaceuticals Inc	Ciertas amidas sustituidas, metodo de elaboracion y metodo de uso de las mismas.
SI1934174T1 (sl)	2005-10-07	2011-08-31	Exelixis Inc	Inhibitorji MEK in postopki za njihovo uporabo
US7838523B2 (en)	2006-09-11	2010-11-23	Cgi Pharmaceuticals, Inc.	Certain substituted amides, method of making, and method of use thereof
AR063946A1 (es)	2006-09-11	2009-03-04	Cgi Pharmaceuticals Inc	Determinadas pirimidinas sustituidas, el uso de las mismas para el tratamiento de enfermedades mediadas por la inhibicion de la actividad de btk y composiciones farmaceuticas que las comprenden.
AR063706A1 (es)	2006-09-11	2009-02-11	Cgi Pharmaceuticals Inc	Determinadas amidas sustituidas, el uso de las mismas para el tratamiento de enfermedades mediadas por la inhibicion de la actividad de btk y composiciones farmaceuticas que las comprenden.
DK2526933T3 (en) *	2006-09-22	2015-05-18	Pharmacyclics Inc	Inhibitors of Bruton's tyrosine kinase
CL2008002793A1 (es) *	2007-09-20	2009-09-04	Cgi Pharmaceuticals Inc	Compuestos derivados de amidas sustituidas, inhibidores de la actividad de btk; composicion farmaceutica que los comprende; utiles en el tratamiento del cancer, trastornos oseos, enfermedades autoinmunes, entre otras
CN101835755B (zh) *	2007-10-23	2013-12-11	霍夫曼-拉罗奇有限公司	激酶抑制剂
US8426441B2 (en)	2007-12-14	2013-04-23	Roche Palo Alto Llc	Inhibitors of bruton's tyrosine kinase
US7683064B2 (en)	2008-02-05	2010-03-23	Roche Palo Alto Llc	Inhibitors of Bruton's tyrosine kinase
PL2242749T3 (pl) *	2008-02-05	2013-09-30	Hoffmann La Roche	Nowe pirydynony i pirydazynony
CA2723237A1 (en)	2008-05-06	2009-11-12	Peter A. Blomgren	Substituted amides, method of making, and use as btk inhibitors
PH12012502374A1 (en) *	2008-06-24	2014-11-12	Hoffmann La Roche	Novel substituted pyridin-2-ones and pyridazin-3-ones
PE20110164A1 (es)	2008-07-02	2011-03-28	Hoffmann La Roche	Nuevas fenilpirazinonas como inhibidores de quinasa
CA2636807A1 (en)	2008-07-04	2010-01-04	Steven Splinter	Methods for obtaining cyclopamine
WO2010006947A1 (en)	2008-07-15	2010-01-21	F. Hoffmann-La Roche Ag	Novel phenyl-imidazopyridines and pyridazines
US8598174B2 (en)	2008-11-12	2013-12-03	Genetech, Inc.	Pyridazinones, method of making, and method of use thereof
US8299077B2 (en) *	2009-03-02	2012-10-30	Roche Palo Alto Llc	Inhibitors of Bruton's tyrosine kinase
WO2010122038A1 (en) *	2009-04-24	2010-10-28	F. Hoffmann-La Roche Ag	Inhibitors of bruton's tyrosine kinase
US8765754B2 (en) *	2009-04-29	2014-07-01	Locus Pharmaceuticals, Inc.	Pyrrolotriazine compounds
NZ598985A (en) *	2009-09-04	2013-07-26	Biogen Idec Inc	Bruton's tyrosine kinase inhibitors
EP2566869B1 (en) *	2010-05-07	2016-03-02	Gilead Connecticut, Inc.	Pyridone and aza-pyridone compounds and methods of use
AR082590A1 (es) *	2010-08-12	2012-12-19	Hoffmann La Roche	Inhibidores de la tirosina-quinasa de bruton
US8975260B2 (en)	2010-09-01	2015-03-10	Genetech, Inc	Pyridazinones, method of making, and method of use thereof
CA2809836C (en)	2010-09-01	2019-01-15	Gilead Connecticut, Inc.	Pyridinones/pyrazinones, method of making, and method of use thereof for the treatment of disorders mediated by bruton's tyrosine kinase
AU2012257802A1 (en)	2011-05-17	2013-10-31	F. Hoffmann-La Roche Ag	Inhibitors of Bruton's tyrosine kinase
CA2841801A1 (en)	2011-08-17	2013-02-21	F.Hoffmann-La Roche Ag	Inhibitors of bruton's tyrosine kinase
EP2773639B1 (en) *	2011-11-03	2017-04-26	F. Hoffmann-La Roche AG	Alkylated piperazine compounds as inhibitors of btk activity
UA111756C2 (uk) *	2011-11-03	2016-06-10	Ф. Хоффманн-Ля Рош Аг	Сполуки гетероарилпіридону та азапіридону як інгібітори тирозинкінази брутона
MX2014005282A (es) *	2011-11-03	2014-05-30	Hoffmann La Roche	Compuestos de 8-fluoroftalazin-1 (2h) -ona.
WO2015000949A1 (en) *	2013-07-03	2015-01-08	F. Hoffmann-La Roche Ag	Heteroaryl pyridone and aza-pyridone amide compounds
WO2015082583A1 (en) *	2013-12-05	2015-06-11	F. Hoffmann-La Roche Ag	Heteroaryl pyridone and aza-pyridone compounds with electrophilic functionality
WO2017148837A1 (en) *	2016-02-29	2017-09-08	F. Hoffmann-La Roche Ag	Dosage form compositions comprising an inhibitor of bruton's tyrosine kinase

2012
- 2012-02-11 UA UAA201405799A patent/UA111756C2/uk unknown
- 2012-11-02 MX MX2014005331A patent/MX2014005331A/es active IP Right Grant
- 2012-11-02 TW TW101140919A patent/TWI609868B/zh active
- 2012-11-02 MX MX2015003514A patent/MX361807B/es unknown
- 2012-11-02 KR KR1020147014661A patent/KR101659193B1/ko active Active
- 2012-11-02 EP EP21171114.8A patent/EP4019508A1/en active Pending
- 2012-11-02 SI SI201231643T patent/SI3002284T1/sl unknown
- 2012-11-02 EP EP19152979.1A patent/EP3521288B1/en active Active
- 2012-11-02 PT PT127838373T patent/PT2773638E/pt unknown
- 2012-11-02 CN CN201280065965.8A patent/CN104125959B/zh active Active
- 2012-11-02 SG SG11201401992YA patent/SG11201401992YA/en unknown
- 2012-11-02 JP JP2014541114A patent/JP5976827B2/ja active Active
- 2012-11-02 HR HRP20151442TT patent/HRP20151442T1/hr unknown
- 2012-11-02 EP EP12783837.3A patent/EP2773638B1/en active Active
- 2012-11-02 DK DK15188086.1T patent/DK3002284T3/da active
- 2012-11-02 HU HUE15188086A patent/HUE044959T2/hu unknown
- 2012-11-02 ES ES15188086T patent/ES2738329T3/es active Active
- 2012-11-02 DK DK12783837.3T patent/DK2773638T3/en active
- 2012-11-02 CN CN201710227680.4A patent/CN107011348B/zh active Active
- 2012-11-02 PL PL19152979T patent/PL3521288T3/pl unknown
- 2012-11-02 TW TW109129648A patent/TW202124384A/zh unknown
- 2012-11-02 LT LTEP15188086.1T patent/LT3002284T/lt unknown
- 2012-11-02 HU HUE12783837A patent/HUE028019T2/en unknown
- 2012-11-02 EA EA201490858A patent/EA023263B1/ru unknown
- 2012-11-02 TW TW107141781A patent/TWI701250B/zh active
- 2012-11-02 IN IN3250CHN2014 patent/IN2014CN03250A/en unknown
- 2012-11-02 RS RS20190888A patent/RS59016B1/sr unknown
- 2012-11-02 PH PH1/2014/500936A patent/PH12014500936A1/en unknown
- 2012-11-02 WO PCT/US2012/063194 patent/WO2013067274A1/en not_active Ceased
- 2012-11-02 US US13/667,133 patent/US8716274B2/en not_active Ceased
- 2012-11-02 PE PE2014000638A patent/PE20141586A1/es active IP Right Grant
- 2012-11-02 AR ARP120104128A patent/AR088641A1/es active IP Right Grant
- 2012-11-02 AU AU2012332365A patent/AU2012332365B2/en active Active
- 2012-11-02 PT PT15188086T patent/PT3002284T/pt unknown
- 2012-11-02 SI SI201230367T patent/SI2773638T1/sl unknown
- 2012-11-02 EP EP15188086.1A patent/EP3002284B1/en active Active
- 2012-11-02 TR TR2019/09849T patent/TR201909849T4/tr unknown
- 2012-11-02 PL PL12783837T patent/PL2773638T3/pl unknown
- 2012-11-02 ES ES19152979T patent/ES2898938T3/es active Active
- 2012-11-02 KR KR1020157036122A patent/KR20160003328A/ko not_active Withdrawn
- 2012-11-02 TW TW106130019A patent/TWI652270B/zh active
- 2012-11-02 EP EP22157147.4A patent/EP4050012A1/en active Pending
- 2012-11-02 RS RS20160001A patent/RS54505B1/sr unknown
- 2012-11-02 PL PL15188086T patent/PL3002284T3/pl unknown
- 2012-11-02 CA CA2853975A patent/CA2853975C/en active Active
- 2012-11-02 ES ES12783837.3T patent/ES2555168T3/es active Active
2014
- 2014-03-13 US US14/207,966 patent/US8921353B2/en active Active
- 2014-04-10 IL IL232060A patent/IL232060A/en active IP Right Grant
- 2014-04-28 CR CR20140194A patent/CR20140194A/es unknown
- 2014-04-28 CO CO14090476A patent/CO6950472A2/es active IP Right Grant
- 2014-04-29 CL CL2014001103A patent/CL2014001103A1/es unknown
- 2014-05-27 MA MA37075A patent/MA35819B1/fr unknown
- 2014-09-08 US US14/479,529 patent/US9238655B2/en active Active
2015
- 2015-08-24 JP JP2015165300A patent/JP2016028046A/ja not_active Withdrawn
- 2015-11-17 US US14/943,552 patent/US9782405B2/en active Active
2016
- 2016-01-04 CY CY20161100003T patent/CY1117097T1/el unknown
- 2016-12-15 AU AU2016273930A patent/AU2016273930B2/en active Active
2017
- 2017-08-31 US US15/693,022 patent/US10045983B2/en active Active
2018
- 2018-01-04 JP JP2018000309A patent/JP6571215B2/ja active Active
- 2018-03-05 AU AU2018201557A patent/AU2018201557B2/en active Active
- 2018-06-27 US US16/020,270 patent/US20190194203A1/en not_active Abandoned
- 2018-07-16 ZA ZA2018/04727A patent/ZA201804727B/en unknown
- 2018-10-30 US US16/175,278 patent/USRE48239E1/en active Active
2019
- 2019-02-14 JP JP2019024668A patent/JP2019108342A/ja not_active Withdrawn
- 2019-07-18 HR HRP20191307TT patent/HRP20191307T1/hr unknown
- 2019-08-16 AU AU2019216728A patent/AU2019216728B2/en active Active
- 2019-10-31 US US16/670,898 patent/US20200062769A1/en not_active Abandoned
- 2019-12-23 AR ARP190103844A patent/AR117501A2/es unknown
2020
- 2020-04-22 AU AU2020202707A patent/AU2020202707B2/en active Active
- 2020-07-02 JP JP2020114594A patent/JP2020183397A/ja not_active Withdrawn
- 2020-08-24 US US17/001,205 patent/US20210079002A1/en not_active Abandoned
2022
- 2022-12-20 US US18/069,099 patent/US20230279012A1/en not_active Abandoned
2023
- 2023-11-29 US US18/523,284 patent/US20240270747A1/en active Pending

Also Published As

Publication number	Publication date
DK2773638T3 (en)	2015-10-19
TR201909849T4 (tr)	2019-07-22
IL232060A0 (en)	2014-05-28
KR20140096097A (ko)	2014-08-04
HUE028019T2 (en)	2016-11-28
EP3002284B1 (en)	2019-05-22
US10045983B2 (en)	2018-08-14
HK1201265A1 (en)	2015-08-28
US20140194408A1 (en)	2014-07-10
AU2018201557B2 (en)	2019-09-19
US20200062769A1 (en)	2020-02-27
PH12014500936A1 (en)	2014-06-09
WO2013067274A1 (en)	2013-05-10
EP4050012A1 (en)	2022-08-31
HRP20191307T1 (hr)	2019-10-18
US20210079002A1 (en)	2021-03-18
EP4019508A1 (en)	2022-06-29
TW201906845A (zh)	2019-02-16
PE20141586A1 (es)	2014-10-25
PT3002284T (pt)	2019-07-17
AU2016273930A1 (en)	2017-01-12
US20130116235A1 (en)	2013-05-09
PL3002284T3 (pl)	2019-11-29
US20190194203A1 (en)	2019-06-27
MX2014005331A (es)	2014-05-28
AU2019216728B2 (en)	2020-04-09
ES2555168T3 (es)	2015-12-29
ES2898938T3 (es)	2022-03-09
AU2012332365A1 (en)	2014-05-01
US20240270747A1 (en)	2024-08-15
EP3521288A1 (en)	2019-08-07
EP3521288B1 (en)	2021-09-08
DK3002284T3 (da)	2019-07-29
PT2773638E (pt)	2016-01-12
PL3521288T3 (pl)	2021-12-27
SI3002284T1 (sl)	2019-08-30
CN107011348B (zh)	2020-01-10
US8921353B2 (en)	2014-12-30
AU2020202707A1 (en)	2020-05-14
HRP20151442T1 (hr)	2016-01-29
ES2738329T3 (es)	2020-01-22
EA201490858A1 (ru)	2014-08-29
AR088641A1 (es)	2014-06-25
LT3002284T (lt)	2019-08-12
JP2014532762A (ja)	2014-12-08
AR117501A2 (es)	2021-08-11
TWI701250B (zh)	2020-08-11
BR112014010459A2 (pt)	2017-04-18
US20140378432A1 (en)	2014-12-25
UA111756C2 (uk)	2016-06-10
CA2853975A1 (en)	2013-05-10
JP6571215B2 (ja)	2019-09-04
HUE044959T2 (hu)	2019-12-30
IN2014CN03250A (2)	2015-07-03
TW201326175A (zh)	2013-07-01
US8716274B2 (en)	2014-05-06
US20180071286A1 (en)	2018-03-15
EA023263B1 (ru)	2016-05-31
RS59016B1 (sr)	2019-08-30
TWI652270B (zh)	2019-03-01
US9782405B2 (en)	2017-10-10
CA2853975C (en)	2020-02-25
JP5976827B2 (ja)	2016-08-24
AU2018201557A1 (en)	2018-03-22
USRE48239E1 (en)	2020-10-06
US20160228432A1 (en)	2016-08-11
CR20140194A (es)	2014-06-03
KR101659193B1 (ko)	2016-09-22
SI2773638T1 (sl)	2015-12-31
TW201741315A (zh)	2017-12-01
NZ624021A (en)	2016-09-30
JP2020183397A (ja)	2020-11-12
CN107011348A (zh)	2017-08-04
AU2016273930B2 (en)	2018-03-08
CO6950472A2 (es)	2014-05-20
CY1117097T1 (el)	2017-04-05
US9238655B2 (en)	2016-01-19
MA35819B1 (fr)	2014-12-01
ZA201804727B (en)	2023-03-29
TW202124384A (zh)	2021-07-01
JP2019108342A (ja)	2019-07-04
KR20160003328A (ko)	2016-01-08
CL2014001103A1 (es)	2014-10-03
EP2773638B1 (en)	2015-10-07
JP2018080193A (ja)	2018-05-24
AU2020202707B2 (en)	2021-09-02
CN104125959A (zh)	2014-10-29
MX361807B (es)	2018-12-17
CN104125959B (zh)	2017-05-03
AU2019216728A1 (en)	2019-09-05
EP2773638A1 (en)	2014-09-10
RS54505B1 (sr)	2016-06-30
TWI609868B (zh)	2018-01-01
IL232060A (en)	2016-02-29
JP2016028046A (ja)	2016-02-25
US20230279012A1 (en)	2023-09-07
PL2773638T3 (pl)	2016-03-31
AU2012332365B2 (en)	2016-09-15
EP3002284A1 (en)	2016-04-06

Publication	Publication Date	Title
ZA201804727B (en)	2023-03-29	Heteroaryl pyridone and aza-pyridone compounds as inhibitors of btk activity
IL266168A (en)	2019-06-30	Heteroaryl compounds and methods of their use
ZA201209205B (en)	2013-08-28	Pyridone and aza-pyridone compounds and methods of use
IL238409A0 (en)	2015-06-30	Heteroaryl inhibitors of pde4
ZA201307632B (en)	2017-06-28	Compositions and methods for the production of pyrimidine and pyridine compounds with btk inhibitory activity
EP2663565A2 (en)	2013-11-20	Heteroaryl compounds and methods of use thereof
ZA201403158B (en)	2017-09-27	Alkylated piperazine compounds as inhibitors of btk activity
ZA201401653B (en)	2019-09-25	Pyrazol-4yl-heterocyclyl-carboxamide compounds and methods of use
EP2758387A4 (en)	2015-03-11	Pyridine compounds as kinase inhibitors
EP2709999A4 (en)	2014-11-19	QUINAZOLINE-7-ETHER COMPOUNDS AND METHODS OF USE
ZA201408856B (en)	2017-06-28	Heteroaryl compounds and methods of use thereof
IL232170A0 (en)	2014-06-30	Heterocyclic carboxamides are useful as phosphodiesterase type 10a inhibitors
TH1401002406B (th)	2016-06-07	สารประกอบเฮทเทอโรเอริล ไพริโดน และ อะซา-ไพริโดนในรูปสารยับยั้งของ btk แอคตีวิตี้
HK1191650A (en)	2014-08-01	Picolinamide inhibitors of kinases